Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections | PHASE2 | COMPLETED | - | — | — | Oct 1, 2001 | May 1, 2004 | Dec 5, 2022 | 1 | United States |
| NCT00062816 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs | PHASE1 | COMPLETED | 22 | — | — | Jun 1, 2003 | Jan 1, 2004 | Dec 5, 2022 | 25 | United States |
| Name | Type | Description |
|---|---|---|
| ISIS 14803 | DRUG | - |
| ISIS 14803, peginterferon alfa, ribavirin | DRUG | - |
Inclusion Criteria Patients must meet the following inclusion criteria during screening: * Age greater than or equal to 18 years. * Both males and females are eligible. All patients should be advised that there are no data on the possible reproductive (teratological) effects of ISIS 14803. Theref...